Product Images Zolmitriptan

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Zolmitriptan NDC 31722-458 by Camber Pharmaceuticals Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

2.5 mg - 2.5mg CRT

2.5 mg - 2.5mg CRT

This is a product label for Zolmitriptan tablets that come in a blister card of six (6) unit-dose tablets. Pharmacists are required to dispense a patient information leaflet to each patient. The label also includes a series of alphanumeric codes that are likely part of a barcode.*

5 mg - 5mg CRT

5 mg - 5mg CRT

This is a product description for Zolmitriptan tablets, a pharmaceutical product used to treat migraines. It includes information about the packaging and dosage of the tablets. It also instructs pharmacists to provide a patient information leaflet with each prescription. The rest of the text appears to be a mix of gibberish and non-English characters.*

Figure 1 - fig1

Figure 1 - fig1

This text describes a figure showing the estimated probability of achieving initial headache response within 4 hours of treatment in pooled studies 2, 3, and 5. The figure is a Kaplan-Meier plot based on data from 3 outpatient trials, and patients who did not achieve headache response or took additional treatment prior to 4 hours were censored at 4 hours.*

Figure 2 - fig2

Figure 2 - fig2

Structure - structure

Structure - structure

Table 1 - tab1

Table 1 - tab1

Table 1 shows the incidence of adverse reactions in five placebo-controlled clinical trials for migraines where Zolmitriptan was used at different dosages. The table presents the percentage of patients experiencing adverse reactions, including atypical sensations, pain, and pressure sensations, digestive issues, neurological symptoms, and other symptoms. Only reactions that were 29% or more frequent in the Zolmitriptan group compared to the placebo group are included in the table.*

Table 2 - tab2

Table 2 - tab2

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.